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A searchable cross-platform gene expression




Background: Transcriptional data covering multiple platforms and species is collected and processed into a
searchable platform independent expression database (SPIED). SPIED consists of over 100,000 expression fold
profiles defined independently of control/treatment assignment and mapped to non-redundant gene lists. The
database is thus searchable with query profiles defined over genes alone. The motivation behind SPIED is that
transcriptional profiles can be quantitatively compared and ranked and thus serve as effective surrogates for
comparing the underlying biological states across multiple experiments.
Results: Drug perturbation, cancer and neurodegenerative disease derived transcriptional profiles are shown to be
effective descriptors of the underlying biology as they return related drugs and pathologies from SPIED. In the case
of Alzheimer’s disease there is high transcriptional overlap with other neurodegenerative conditions and rodent
models of neurodegeneration and nerve injury. Combining the query signature with correlating profiles allows for
the definition of a tight neurodegeneration signature that successfully highlights many neuroprotective drugs in
the Broad connectivity map.
Conclusions: Quantitative querying of expression data from across the totality of deposited experiments is an effective
way of discovering connections between different biological systems and in particular that between drug action and
biological disease state. Examples in cancer and neurodegenerative conditions validate the utility of SPIED.
Keywords: Global gene expression, connectivity map, microarray, cancer, neurodegenerative disease, Alzheimer’s
disease
Background
There is a wealth of deposited gene expression data
available for downloading and/or online interrogation.
For example, the NCBI gene expression omnibus (GEO)
[1] hosts over half a million single array chip expression
profiles and the EBI hosts the ArrayExpress [2] database
with a similar largely overlapping number of arrays.
These data cannot be compared directly as they come
from different array platforms covering many different
species and a variety of normalisation schemes are used.
In the overwhelming number of analyses expression
profiles are compared within the given series and
probed for the up or down regulation of single genes
using volcano plot representations or other statistical
filters [3]. Alternatively, a larger set of responders can
be scored against gene sets corresponding to pathways
[4], interacting networks [5-7] or gene ontology classes
[8,9]. For large series it is possible to compile correla-
tions of expression changes of individual gene pairs and
groups of genes leading to a hierarchical clustering
based network discovery and gene interaction predic-
tion. To this end SOURCE [10] hosts gene expression
profiles across a large collection of experimental series
and profile correlations within a given series can be exam-
ined to predict genes with similar or related function.
Many array analysis applications incorporate array derived
network data that are valuable aids in characterising the
expression profile data (Ingenuity Pathways Analysis (IPA)
(Ingenuity® Systems, http://www.ingenuity.com); GeneGo
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(GeneGo, Inc., St. Joseph, MI)). However, these analyses
do not allow for a direct quantitative comparison between
separate expression studies and therefore a lot of the infor-
mation contained in the experiment is effectively lost.
The idea that transcriptional change profiles can be
directly compared to asses drug target specificity was
demonstrated in yeast systems by Marton et al [11] and
later extended by Hughes et al [12]. The connectivity
map (CMAP) project sought to apply these ideas to gen-
erate a database of drug perturbagen transcriptional pro-
files that can be searched with transcriptional responder
sets by third parties to match phenotype to drug treat-
ment [13]. In this methodology the expression change
profile as a whole defines the biological perturbation and
not a relatively small selection of down- or up-regulated
genes. An important point here is that biological effects
are not necessarily caused by the corresponding tran-
scriptional changes. Rather, the underlying assumption is
that correlations in transcriptional change profiles are
reflected in similar biological responses. One powerful
application of the CMAP is the matching of disease state
to drug treatment. In simple terms, if a disease state is
reflected in a well defined transcriptional response, then
a drug that has the opposite effect on expression of these
transcripts might be of therapeutic value. The fundamen-
tal assumption here is that there is a degree of overlap in
the transcriptional changes induced by the same pertur-
bagen in different cell contexts. In particular the CMAP
consist of expression change data for human cancer cell
lines and it is hoped that there is a degree of universality
that will enable useful predictions to be made as to the
action of the drugs in different cell types. Of course, the
successful application of the CMAP should encourage
rather than hinder the inclusion of other cell types more
relevant to the type of biological system under investiga-
tion. At the present the CMAP consists of expression
change fold profiles for 6,100 single treatments versus
control pairs for a collection of 1,309 drug like perturba-
gens. Results are collected from treatments of four dis-
tinct types of human cancer cell lines. The CMAP
database can be interrogated with expression change sig-
natures consisting of lists of up and down regulated
probe sets. Correlation both in the positive and negative
sense are scored by means of a non-parametric Kolmo-
gorov-Smirnov (KS) statistic [14]. The remarkable obser-
vation was that signatures from published studies showed
correlation with CMAP profiles for drugs known to act
against the same targets. This has opened the way for the
CMAP to be used as a drug discovery tool where it is
probed with signatures encoding disease states.
If the CMAP methodology is accepted as a useful dis-
covery tool then it is natural to look for ways of extending
it to incorporate expression data from a wider set of
experiments. There are obvious advantages to having this
kind of database, for example it will open up a large num-
ber of different samples and treatment conditions for
direct interrogation. This was the idea behind GEM-
TREND [15], where 26,000 expression samples from
various platforms and species were compiled into a
searchable database. The search methodology mirrors that
of CMAP in that the database consists of ranked lists of
genes and it is interrogated with up and down regulated
gene sets and query signatures are scored by a KS statistic
with the significance based on reference to random gene
set scores. One difference to the CMAP database is neces-
sitated by the multiple origins of the expression profile
data represented by multiple probe ID definitions. The
problem of multiple probe IDs is solved by the GEM-
TREND database having expression profiles mapped onto
UniGene IDs. The database consists of experimental series
where samples can be clearly assigned to treatment and
control groups. Of course, this is not always the case and
this limits the scope of the database.
In compiling the expression database SPIED we sought
to loosen the restraints inherent in previous treatments
and thereby open up a larger set of data for interrogation.
In many expression series sets there is no clear control/
treatment assignment or there could be multiple alterna-
tive reference profile definitions. To address this problem
of generating fold change profiles without reference to a
defined control, an effective fold (EF) has been intro-
duced corresponding to the expression level relative to
the experimental series average. In this way, data can be
compiled automatically without the need for manual
inspection. In cases where the experimental series con-
sists of well defined multiple treatment and control sam-
ples the fold profiles are usually given by the ratio of the
average treatment to average control values. In general
this fold profile will have high positive correlation with
the EF profiles from the treatment set and high negative
correlations with the control set. In cases where there is
no obvious way of separating samples into control and
treatment sets, as with samples from multiple organ
types or cell types, the EF representation can be viewed
as a normalized expression value. In searching SPIED
with a query profile one is not deriving any biological sig-
nificance for non-correlating profiles as lack of correla-
tion can be attributed to multiple factors such as bad
experimental data or genuine lack of biological relevance.
Rather significantly correlating or anti-correlating pro-
files are posited as having biological significance. The
next objective was to reduce the expression profiles to
non-redundant EF gene profiles by associating each gene
with just one probe ID, so that the database can then be
searched with gene set data alone. Here, for a given chip
platform the distribution of each probe ID EF value
across the totality of series was compiled and each gene
was then assigned to the probe having the highest
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average fold magnitude. The gene names were unam-
biguously associated with the Entrez human gene list
(http://www.ncbi.nlm.nih.gov), consisting of 24,764 genes
and these were matched to probe IDs by inspection of
the given platform annotation files. The final form of
SPIED consists of individual files for each chip platform
and these files are formatted starting with a gene list fol-
lowed by the sample ID and corresponding EF profiles.
This format lends itself to rapid searching in an analo-
gous fashion to FASTA formatted sequence databases. In
contrast to the KS query score scheme, which requires
generating random reference gene list data, we adopted a
simple regression scoring scheme with corresponding
statistic. Searches can be performed on a standard desk-
top PC and take ~10 minutes per query. Although, the
present database consisting of expression data for over
100,000 samples from five platforms covering three spe-
cies (human, mouse and rat) is all from Affymetrix
expression array chips, the methodology is truly platform
independent and it is a straight forward matter to include
data based on other array technologies. Other species
and platform technologies will be added to SPIED in the
future. For the present study Affymetrix was chosen
because of the relatively large number of available sam-
ples. Further details are presented in the methods section
below.
Results
Drug treatment based profile SPIED queries
The CMAP contains expression change profiles as
ranked array probe IDs for 6,100 individual treatments
corresponding to 1,309 distinct drug-like compounds.
Statistically filtered response profiles can be defined for
1,218 of the drugs as these have at least three instances
in the database. The profiles can be mapped onto a non-
redundant gene list by uniquely associating one probe ID
to a given gene and dropping the other probe ID for this
gene with less robust expression changes over the data-
base. This is the same methodology underlying the
SPIED database. We took the responder profiles for the
1,218 drugs and searched the SPIED for maximally (anti-
)correlated expression change profiles. The objective is to
see to what extent the CMAP transcriptional signatures
correlate with transcriptional responses assimilated
within our platform independent database of over
100,000 microarrays deposited by a very large number of
groups to the public domain.
The CMAP is well populated with drugs that target
the same or different steps in the PI3K-mTOR signalling
cascade. In this context the results for LY-294002 (PI3K
inhibitor) (61 instances), rapamycin (mTOR antagonist)
(44 instances) and wortmannin (PI3K/mTOR antago-
nist) (18 instances) showed a high degree of overlap
(rapamycin v LY-294002 r = 0.90 N = 3565, rapamycin
v wotmannin r = 0.91 N = 1849, LY-294002 v wotman-
nin r = 0.88 N = 2217, where r is the Pearson correla-
tion coefficient and N is the number of shared genes
with significant fold values), see additional file 1 for the
full fold change data. It is a straightforward matter to
query the SPIED with these drug expression profiles.
This is done by calculating the regression scores against
the individual SPIED entries and retaining the top ~100
correlations, see Methods for details. For simplicity and
uniformity of treatment, unless otherwise stated, we
query SPIED with expression profiles containing 500
genes with the largest fold values passing the p < 0.05
significance threshold. It should be noted that results
will be largely insensitive to the size of the query profile.
The top SPIED correlate for all three drugs was the
Pan-PI3K inhibitor GDC-0941 treated T47D breast can-
cer cells and the regression scores for the tree query sig-
natures against all 6 samples in the series are shown in
Figure 1A. The high degree of correlation is illustrated
by regression plots for the three query profiles against
the pooled GDC-0941 profile, see Figure 1B, C, D. All
three inhibitor queries also pick out mTOR antagonist
studies [16], but a more interesting correlation is with a
glucocorticoid (dexamethasone) treatment of acute lym-
phoblastic leukaemia (ALL) cells [17], the rapamycin
scores are shown in Figure 2A. The correlation increases
with the length of drug treatment, being higher at 24
hours, Figure 2B, C. This result reveals another connec-
tion between mTOR antagonism and the corticosteroid
mechanism as it has been shown that corticosteroid
resistance in ALL can be overcome by mTOR antagon-
ism [18]. Chronic myeloid Leukaemia (CML) and some
instances of ALL are the result of the ABL tyrosine
kinase translocation and fusion to BCR, the BCR-ABL
fusion event [19]. This pathology has been targeted with
rapamycin and our results support this approach based
on the high degree of anti-correlation of the CMAP
rapamycin profile with a transcriptional profile of BCR
fusion construct transformed chord blood cells. The
correlation scores are shown in Figure 3A. There is a
clear anti-correlation of rapamycin profile with the
BCR-ABL profiles pointing to a possible reversal of the
phenotype, Figure 3B. Also, there is a high anti-correla-
tion with the BCR-FGFR1 profile indicating a possible
therapeutic role of rapamycin, Figure 3C.
In the original CMAP presentation [13] it was shown that
meaningful results can be obtained from anti-correlating
profiles. In particular the estrogen transcriptional
response was shown to anti-correlate with the profiles of
estrogen antagonists fulvestrant, tamoxifen and raloxi-
fene. In this context it is of interest to note that high
scoring SPIED hits for all three antagonists corresponded
to anti-correlations with estrogen treatment samples. We
have shown one example in Table 1 corresponding to a
Williams BMC Genomics 2012, 13:12
http://www.biomedcentral.com/1471-2164/13/12
Page 3 of 14
estrogen, tamoxifen and an extract from the cimicifuga
plant [20].
For illustration purposes we have shown the common
high correlating hits for three separate histone deacety-
lase (HDAC) inhibitor profiles in the CMAP series.
These are vorinistat, trichostatin A and valporic acid. In
Table 2 we have shown the regression scores for the mul-
tiple HDAC inhibitor study with a colorectal carcinoma
cell line [21]. The query results for all the above searches
are given in additional file 2.
Next we consider profiles derived from disease states.
For brevity we focus on two unrelated pathologies: can-
cer and neurodegeneration.
Querying SPIED with cancer derived profiles
The class of diseases with the most extensive repository
of expression data is cancer and therefore a cancer dis-
ease profile search of SPIED will be an ideal testing
ground for the methodology. The original CMAP disease
application implicated mTOR inhibition as a target for
imparting sensitivity to dexamethasone treatment
resistant ALL [18]. We searched the SPIED database with
the dexamethasone resistant v sensitive profile to see if
there are common features in published transcriptional
studies. The query profile consisted of the 500 most
highly regulated genes that passed the lowest significance
test of p < 0.05, see additional file 1. As with the SPIED
profiles the query profile also consists of a non-redun-
dant gene list. Not surprisingly, the highest correlation
scores came from the experiments from which the query
profile was generated, see additional file 2 file. In addi-
tion, we found a high correlation to an independent later
study of ALL sensitivity to corticosteroid (prednisolone)
treatment [22]. This study generated transcriptional pro-
files of ALL patient leukaemia cells with the objective of
uncovering a gene signature that can predict the sensitiv-
ity to prednisolone treatment. Combining the 27 infant
and non-infant corticosteroid sensitive samples and the
25 resistant samples we can define a statistically filtered
sensitivity profile to make a direct comparison with the
query profile and we find a high degree of correlation
(r = 0.94), see additional file 2. When the high scoring
Figure 1 High scoring correlations in the SPIED with queries derived from the CMAP profiles of rapamycin, LY-294002 and
wortmannin are with a pI3 kinase inhibitor GDS-0941. The individual sample scores and the regression scores (in this and later Figures/
Tables r is the Pearson correlation coefficient and N is the number of genes in the given correlation) with the treatment and control groups are
shown in A. The pooled profiles are defined by the ratios of the treatment to control averages. The fold regression plots are given in B, C and D.
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sample belongs to a relatively large sample series and the
phenotype is binary we can perform a non-parametric
significance test to measure the extent of enrichment of
the given phenotype for high or low correlation scores.
For example in the last case there were 25 resistant and
27 sensitive samples. Ranking the samples according to
their correlation with the resistant versus sensitive query
profile we find 20 resistant samples in the top 25 and 22
sensitive samples in the bottom 27. This is highly signifi-
cant and can be quantified with a simple Fisher exact
test. Explicitly, the probability p of 20 or more resistant
samples in the top 25 correlations is less than 9 × 10-7.
The K-S significance score can be calculated by counting
the number of times a random rearrangement of the
samples gives a better enrichment, we find p < 3 × 10-6.
The enrichment plot is given in Figure 4A. As expected
the top scoring correlations were dominated by samples
from blood derived cells, for simplicity we restricted our
analysis to the top 100 most significantly correlating sam-
ples. However, two studies in unrelated tissue pathologies
Figure 2 The CMAP rapamycin query score highly against a glucocorticoid treatment experiment. The correlations with the individual
samples are shown in A and the regression plots for the pooled treatment and control groups are shown at 24 hours in B and at 6 hours in C.
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were highly correlated with the corticosteroid resistant
profile. These were a comparison of lung epithelia with
cancer in smokers [23] and a differential expression
between healthy and cancerous pancreatic tissue [24].
The smoking study consisted of non-diseased lung
epithelia from 187 individual smokers 97 of whom were
diagnosed with lung cancer. Ranking the samples accord-
ing to query correlation score we find that in the top 97
there are 64 cancer cases and in the bottom 90 there are
57 non-cancer cases, with a significance score of p < 5 ×
10-5. The K-S significance is p < 2 × 10-4. The enrichment
for positive correlations with the corticosteroid resistance
profile in the cancer cases is shown in Figure 4B. Interest-
ingly, it has been shown that there is a down regulation of
the glucocorticoid receptor (GR) in small cell lung cancer
[25,26] and reversing this promotes cancer cell apoptosis
[27]. The pancreatic cancer study sought to establish a
transcriptional signature of tumour versus normal pan-
creatic tissue by laser capture of cancerous and normal tis-
sue from the same pancreas. In total 39 sample pairs were
published and we find a high positive correlation with the
corticosteroid resistance profile, p < 2 × 10-6 and a K-S
significance score of p < 3 × 10-7. The enrichment curve is
shown in Figure 4C. In this context it has been reported
Figure 3 The rapamycin CMAP significantly anti-correlates with the transcriptional changes induced in chord blood cells by two
distinct BCR fusion transformations. The correlations with the individual samples is shown in A and the negative regression with the pooled
BCR/ABL1 transform v control and BCR/FGFR1 transform v control are shown in B and C respectively.
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that loss of GR expression has been seen in pancreatic car-
cinoma relative to normal tissue [28] and elevating GR
expression has been shown to inhibit pancreatic tumour
growth in a hamster model [29]. The query results are
given in the additional file 2.
Neurodegenerative Disease
The analysis of gene expression changes associated with
neurodegenerative disease has been hampered by the
difficulty of extracting high quality RNA from post-mor-
tem tissue [30,31]. One way of validating a disease asso-
ciated gene expression profile is to show that it shares
significant features with profiles derived from indepen-
dent experiments on related pathologies. A positive result
would validate the query profile and furthermore lead to
a more robust core response profile based on multiple
experiments. To this end we constructed three separate
query profiles based on transcriptional profiles from the
brains of patients with three degrees of severity of Alzhei-
mer’s disease (AD) [32], see additional file 1. The number
of significant changes increases with severity of disease
and we queried the SPIED with these three profiles, see
additional file 2. Not surprisingly, the high scoring corre-
lations are those from which the query profiles were
derived. In addition to these the query returned correla-
tions with other AD studies and various neurodegenera-
tive diseases. The high scoring AD expression series was
an extensive study of 161 samples from various brain
regions of AD patients and age-matched controls [33].
Ignoring brain regions for now, there are 87 AD samples
and 74 controls. Ranking the samples according to corre-
lation score against the severe AD query profile we find a
very significant enrichment of positive correlations with
AD samples (p < 10-8, based on the Fisher test as above).
Pooling the samples from the different brain regions
results in significant correlations for 5 out of the 6 brain
regions, see Figure 5.
In addition to AD correlations we found high scoring
correlations with samples derived from Huntington’s
disease (HD), Down’s syndrome (DS), Parkinson’s dis-
ease (PD) and bipolar disorder (BD) brains. In this sense
the profile cannot be considered to distinguish AD
pathology from other degenerative diseases. However, it
is of interest to examine in greater detail these cross-dis-
ease similarities. In particular, the severe AD query had
a high correlation with severe stage HD caudate nucleus
(CN) samples. The HD study consisted of 404 samples
split across two platforms (201 samples on GPL96 and
203 on GPL97) in three brain regions from control and
HD individuals [34]. The high correlation was with the
GPL96 series. In terms of a binary Fisher analysis where
brain region specificity is ignored, we get a small enrich-
ment of p < 6 × 10-3. However, when the different brain
regions are considered separately, we get significant
regression scores in each region. The results are tabu-
lated in Table 3.
The PD correlation was with a study of 94 samples
from three different regions of diseased and normal
brains [35]. Pooling samples according to brain region
we find that the severe AD profile had a high correla-
tion with all three regions studied: superior frontal gyrus
(SFG) r = 0.88; lateral substatia nigra (LSN) r = 0.77;
medial substantia nigra (MSN) r = 0.82, see Table 3.
Table 1 Estrogen antagonist queries derived from CMAP
corresponding to raloxfene, fulvestrant and tamoxifen
significantly anti-correlate with an estradiol treatment
experiment.
raloxifene fulvestrant tamoxifen
SAMPLE R N r N R N
GSM155008: 24h_Estradiol_1 -0.52 495 -0.58 496 -0.45 497
GSM155009: 24h_Estradiol_2 -0.52 496 -0.60 498 -0.43 498
GSM155007: 24h_DMSO_2 -0.21 498 -0.08 500 -0.26 499
GSM155006: 24h_DMSO_1 -0.10 493 0.13 492 -0.23 497
GSM155013: 24h_Tamoxifen_2 -0.01 500 -0.06 497 0.04 498
GSM155012: 24h_Tamoxifen_1 0.39 499 0.30 497 0.27 499
GSM155005: 24h_Cimicifuga_2 0.34 497 0.39 498 0.34 500
GSM154972: 24h_Cimicifuga_1 0.48 499 0.41 499 0.39 499
Pooled profiles
Estradiol v DMSO -0.63 58 -0.76 90 -0.46 47
Tamoxifen v DMSO 0.65 26 0.19 24 0.67 22
Cimicifuga v DMSO 0.58 70 0.33 75 0.56 66
Positive correlation is seen with tamoxifen treatment and a herbal extract
cimicifuga. The regression scores for the pooled treatment and control groups
are shown at the bottom of the table.
Table 2 The HDAC inhibitor queries trichostatin A,
vorinostat and valproic acid derived from the CMAP





SAMPLE R N r N r N
GSM548552: 8146_vehicle
control_2
-0.86 492 -0.89 494 -0.65 492
GSM548551: 8145_vehicle
control_1
-0.85 490 -0.88 494 -0.62 491
GSM548546: 8140_LZ_2 0.65 491 0.62 492 0.50 485
GSM548545: 8139_LZ_1 0.66 491 0.61 489 0.52 485
GSM548547: 8141_SAHA_1 0.68 491 0.66 488 0.50 487
GSM548548: 8142_SAHA_2 0.70 492 0.70 489 0.51 485
GSM548550: 8144_FK228_2 0.72 493 0.79 488 0.40 484
GSM548549: 8143_FK228_1 0.75 492 0.81 484 0.45 484
pooled profiles
LZ v control 0.89 388 0.91 382 0.74 303
SAHA v control 0.90 374 0.92 368 0.74 290
FK228 v control 0.88 387 0.92 390 0.69 301
The regression scores for the pooled treatment and control groups are shown
at the bottom of the table.
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The chromosome 21 trisomy underlying DS leads to
the development of many of the characteristics of AD
pathology [36,37]. Therefore, it is not surprising to find
a high correlation in SPIED form a transcriptional pro-
filing of DS brains. This study comprised 8 healthy and
7 DS individual brains [38]. Combining the expression
data into a thresholded fold change profile we find that
there is a significant but small positive correlation with
the severe AD profile, with r = 0.58. Interestingly, the
correlation is higher with the moderate AD profile, with
r = 0.68, see Table 3.
The first transcriptional profiling of BD brains pointed
to the down regulation of synaptic and mitochondrial
proteins in the orbital frontal cortex [39]. This synaptic
pathology picture of BD is further strengthened by our
analysis of the AD profile correlates within SPIED. Pool-
ing the 10 BD samples and 11 controls we find a high
regression score with the severe AD profile, see Table 3
[39]. It is important to note that this correlation is with
a subset of the BD signature as it consists of genes that
are also altered in AD. However, it is outside the scope
of the present paper to combine profiles into disease
specific queries.
Not surprisingly the high correlations are dominated
by experiments on human samples. Perhaps of greater
interest to the biologist are animal models of neurode-
generation. There has indeed been a debate as to the
relevance of animal models of neurodegeneration to
drug discovery, as age-related neurodegenerative condi-
tions are rare in nonhumans [40]. In this context it is
interesting to look at what correlations the AD query
profile returns when we restrict the search to rodent
platforms. The SPIED database contains samples from
two murine and one rat platforms. Within the top 100
high scoring samples we have four separate studies
directly relevant to neuropathology, see additional file 2.
In particular, we find high scores with two separate
spinal contusion models. The mouse experiments gener-
ated a post injury expression time series (GEO accession
GSE5296, also http://pepr.cnmcresearch.org) and the
AD profile correlation emerges at 72 hours post injury,
see Table 4. The other spinal chord contusion study was
in rats at 35 days post injury [41], see Table 4. In addi-
tion to these contusion models high scores were for a
murine SOD1(G93A) mutant model of Amyotrophic lat-
eral sclerosis (ALS) (GEO accession GSE18597) and a
murine model of prion disease (GEO accession
GSE23182). In the SOD1 (G93A) transcriptional profile
series we found the correlation with AD emerging with
older mice, with negligible correlation at the 28-70 day
window and significant correlation with the 98-126 day
late stage window profiles. This is consistent with the
timescale of disease onset in the mouse model [42,43].
Prion disease is modelled in mice through ME7 prion
agent infection resulting in both a behavioural pheno-
type and synaptopathy [44]. The transcriptional study
Figure 4 Enrichment plots for high scoring SPIED hits against the glucocorticoid (dexamethasone) resistant v sensitive profile query.
The dexamethasone resistance query scores highly against a corticosteroid (prednisolone) resistance study. The enrichment plot is shown in A.
Ordering the samples according to correlation score with the query profile the enrichment plot is the cumulative fraction of the given
phenotype in the given sample fraction. Explicitly, if there are N correlation score ordered samples and two phenotypes defined by qi = ± 1







and the enrichment plot is just e+/−k against
k
N
. The plot shows that
sensitive samples are enriched for lower correlation scores and resistant samples are enriched for higher correlation scores. The enrichment plots
for the lung cancer study is shown in B and for the pancreatic cancer study in C.
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corresponded to hippocampal profiles for ME7 v normal
brain homogenate inoculated mice (GEO accession
GSE23182). Pooling the treatment sets we get a good
correlation with the AD profile, see Table 4. Thus it is
clear that there is a core response profile shared across
many neurodegenerative conditions and animal models
of these conditions. Importantly, this core set is charac-
terised by synaptic pathology and mitochondrial dys-
function, both of which are hypothesised to be causative
of a number of neurodegenerative disease states.
It might be thought that we are getting further away
from the specific pathology, in this case AD, and losing
transcriptional information that could be of use in the
hunt for a therapy. This is however not the case as can
be seen when we search the CMAP with a profile com-
posed of genes whose sense change is conserved across
the rodent disease models. Combining the severe AD
profile and the four rodent neurodegenerative disease
model profiles we get a set of 24 genes whose sense
change is conserved. This consists of 10 up regulated
Figure 5 A severe AD query is highly correlated with another AD transcription profiling study in SPIED. The regression scores across six
brain regions are shown in A. All apart from HIP are highly correlated with the severe AD profile. The overall enrichment for positive query
correlation is shown in B (see Figure 4 legend for definition of enrichment plot) and a particular brain region regression plot is illustrated in C.
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and 14 down regulated genes, which can be thought of
as a binary signature for neuropathology, where +1 is
assigned to up-regulated genes and -1 to down-regu-
lated genes, see Table 5. The CMAP drugs with the
highest anti-correlation with this signature are shown in
Table 6. Remarkably, there are at least 9 neuroprotective
agents in the top 22 hits. In particular, Galantamine, a
plant alkaloid, is currently prescribed for early stage AD
[45-48], it was originally studied for its acetylcholinester-
ase inhibitory activity, but it may also act on other tar-
gets [49]. The flavones chrysin [50], apigenin [50,51]
and luteolin [50,52,53] have been reported to have neu-
roprotective activity. As have the two kinase inhibitors
H-7 (PKA/PKC inhibitor)[54] and GW-8510 (CDK inhi-
bitor)[55]. The b-carboline plant alkaloid harmine has
several neuronal actions. It acts to slow down the
Table 3 The severe AD profile query correlates with other
neurodegenerative condition transcriptional changes.
Huntington’s disease in various brain regions
Caudate nucleus Cerebellum Frontal cortex
r N r N r N
severe 0.85 315 0.72 113 0.78 101
moderate 0.73 290 0.39 92 0.22 66
incipient 0.33 124 0.39 48 0.17 44
PD in various brain regions
SFG LSN MSN
r N r N r N
severe 0.88 85 0.77 127 0.82 154
moderate 0.61 74 0.70 104 0.55 134
incipient 0.43 34 0.21 46 0.12 52
Down’s Syndrome Bipolar Disorder
r N r N
severe 0.58 161 severe 0.87 139
moderate 0.68 202 moderate 0.58 73
incipient 0.04 112 incipient 0.03 44
The correlation scores with the severe AD profile are shown for four distinct
neurodegenerative conditions: Huntington’s disease, Parkinson’s disease,
Down’s syndrome and Bipolar disorder.
Table 4 Rodent correlations with the severe AD profile.
Mouse spinal chord injury v sham at injury site
4 h 24 h 72 h 7 d 28 d
R N r N r N r N r N
severe 0.12 55 0.26 131 0.60 148 0.55 148 0.62 139
moderate -0.08 66 0.12 138 0.45 162 0.47 164 0.52 129






young 28-40d old 112-126d
r N r N r N r N
severe 0.76 76 0.70 176 0.07 109 0.49 205
moderate 0.63 63 0.66 158 -0.01 114 0.42 210
incipient 0.50 26 0.11 71 -0.08 76 0.19 105
The severe AD profile is significantly correlated with four different rodent models of neurodegeneration and nerve injury. The correlation in the spinal chord
injury time course study emerges at 72 hours. The ALS SOD1(G93A) profile correlation is only seen with late stage disease.
Table 5 Multi-species derived nerodegenerative
signature.
Gene signature A B C D E
VSNL1 -1 -1.20 -1.19 -0.28 -0.28 -0.50
NEFL -1 -1.06 -0.72 -0.23 -0.42 -0.60
CCK -1 -0.91 -1.12 -0.47 -0.23 -0.85
YWHAH -1 -0.88 -0.38 -0.26 -0.17 -0.39
TUBA4A -1 -0.75 -0.80 -0.45 -0.32 -0.23
YWHAB -1 -0.73 -0.39 -0.72 -0.21 -0.40
NRN1 -1 -0.67 -0.65 -0.67 -0.31 -0.76
GUCY1B3 -1 -0.66 -0.64 -0.30 -0.22 -0.13
SCN1A -1 -0.60 -1.05 -0.62 -0.36 -0.35
SYP -1 -0.54 -0.62 -0.49 -0.26 -0.25
NDRG3 -1 -0.52 -0.58 -0.31 -0.17 -0.33
PPP2R2B -1 -0.42 -0.66 -0.51 -0.25 -0.27
MDH2 -1 -0.42 -0.36 -0.28 -0.13 -0.12
DYNC1I1 -1 -0.39 -1.00 -0.71 -0.35 -0.47
RHOC +1 0.30 0.39 1.03 0.73 0.74
SLC16A1 +1 0.35 0.36 0.69 0.48 0.20
MAPKAPK2 +1 0.40 0.32 0.51 0.37 0.23
CTSB +1 0.43 0.79 0.80 0.86 0.57
DAB2 +1 0.47 1.05 0.94 0.58 0.29
CLU +1 0.47 0.54 0.37 0.50 0.22
TBC1D2B +1 0.51 0.32 0.42 0.18 0.76
ZFP36L1 +1 0.61 0.59 0.98 0.56 0.48
SREBF1 +1 0.63 0.90 0.57 0.36 0.46
MDFIC +1 0.63 0.80 1.43 1.17 0.43
The AD based signature consists of a set of down-regulated (-1) and up-
regulated (+1) genes based on the conservation of gene sense change across
multiple expression studies of neurodegeneration. The five expression profile
fold values are shown with: A, severe AD in human; B, chronic spinal chord
contusion in rat; C, chronic spinal chord contusion in mouse; D, SOD1(G93A)
mutation late stage in mouse; E, prion disease in mouse.
Williams BMC Genomics 2012, 13:12
http://www.biomedcentral.com/1471-2164/13/12
Page 10 of 14
breakdown of monoamine neurotransmitters through
inhibition of monoamine oxidase A [56,57]. Also, it has
been shown to specifically inhibit DYRK1A, an enzyme
responsible for phosphorylation of tau and thereby may
act to slow tau pathology in AD and DS [58,59]. Nomi-
fensine is a dopamine reuptake inhibitor originally pre-
scribed as an anti-depressant [60] that has been shown
to reverse dopaminergic neurotoxicity [61-63] and to
have beneficial effects in Parkinson’s disease [64]. Carba-
chol is an acetylcholine receptor agonist, but with poor
blood brain barrier penetration [65]. The possible appli-
cation of the other high scoring compounds remains to
be determined.
Discussion and Conclusions
We have collected transcriptional data from diverse plat-
form architectures corresponding to various species. By
processing the data into effective fold profiles, with the
expression levels factored by the average level over the
experimental series and defined over a non-redundant
gene list, we can directly compare transcriptional profiles
from arbitrary sources. The fundamental principal underly-
ing the utility of this approach is that biological effects can
be compared through the corresponding transcriptional
changes. This idea underlies the CMAP initiative for
matching drug to phenotype by querying a database of
drug induced transcriptional profiles with a profile defining
the phenotype. We have extended this methodology to
include potentially all available transcriptional data. In its
current version SPIED contains transcriptional profiles for
106,101 arrays covering five platform architectures and
three species. This can be easily extended to include other
platforms and species. The results largely confirm the
hypothesis that high scoring correlations correspond to
similar biological processes. We have presented SPIED
results for drug perturbagen induced profile queries and
queries derived from disease states. For brevity we focussed
on three sets of drug treatment profiles corresponding to
mTOR/PI3K, estrogen and HDAC inhibitors. SPIED
searches with these queries showed correlations with other
drug treatments belonging to the same classes and in the
case of the mTOR antagonist rapamycin we found high
anti-correlations with the profile of a cancer inducing
fusion transformation, suggesting a novel indication for
rapamycin. Also, for brevity of exposition we focussed on
two completely unrelated classes of pathology: cancer and
neurodegeneration. In the case of leukaemia we show that
a corticosteroid resistance signature derived from leukae-
mia cell cultures shows significant correlation with a lung
cancer predisposition profile and a pancreatic cancer pro-
file. Thereby implicating glucocorticoid resistance in these
two pathologies. To illustrate the application of SPIED to
neurodegenerative pathology we constructed a severe stage
AD profile from a published study. Interestingly, querying
SPIED resulted in high correlations with other neuropatho-
logical conditions indicating a common feature of synaptic
loss and mitochondrial dysfunction. Restricting our
searches to the rodent subset of SPIED returned expression
profiles from animal models of neurodegeneration and
neuronal injury. Combining the human and rodent signa-
tures we obtained a core signature that we probed against
CMAP for neuroprotective agents. Remarkably, we found
at least 9 neuroprotective agents in the top 22 anti-corre-
lating CMAP hits. These results motivate the extension of
SPIED and the extension of the CMAP to include other
cell types, for example a neuronal cell lineage will be more
appropriate for generating drug profiles for neurological
diseases. The correlation query scores maybe insensitive to
a radical reduction in the number of probes and this
should motivate the design of reduced and more cost effec-
tive arrays for more extensive data generation.
Methods
Compiling the data
Microarray sample files, GSM files, were downloaded
form the NCBI GEO database. Individual GSM files were
Table 6 Multi-species derived nerodegenerative signature
can pick out neuroprotective drugs in CMAP.
COMPOUND < r > prob N
verteporfin -0.48 0.007 3
lysergol -0.43 0.021 4
N-acetyl-L-leucine -0.41 0.003 4
chrysin -0.41 0.004 3
pipenzolate bromide -0.40 0.033 4
milrinone -0.40 0.030 3
apigenin -0.39 0.017 4
carbachol -0.38 0.006 4
camptothecin -0.38 0.002 3
chlorzoxazone -0.37 0.006 4
amiodarone -0.35 0.002 5
luteolin -0.35 0.008 4
torasemide -0.35 0.020 4
pridinol -0.35 0.004 4
H-7 -0.34 0.002 4
nialamide -0.34 0.047 4
GW-8510 -0.34 0.003 4
trifluridine -0.34 0.017 4
galantamine -0.34 0.010 4
metacycline -0.32 0.046 4
harmine -0.31 0.016 4
nomifensine -0.31 0.023 5
The connectivity map hits for the neurodegeneration signature are given. The
correlation <r > is the average over the drug replicates and the significance is
measured with the Student’s t-test. Drugs with established neuroprotective
activity are highlighted in bold.
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assigned to GSE series and log scaled values scaled to lin-
ear and low level responders dropped. EF profiles were
then generated based on ratio of individual condition to
the average across the series. Expression data from five
Affymetrix GeneChip platforms corresponding to three
species were collected. These were: all samples from two
Human array platforms corresponding to Human Gen-
ome U133 Array Set HG-U133A GPL96 (27,337 samples)
and U133 Plus 2.0 Array GPL570 (55,196 samples); all
samples from the Mouse Genome 430 2.0 Array
GPL1261 (21,219 samples) chip; all samples from two
Rat chips corresponding to Rat Genome U34 Array
GPL85 (2,827 samples) and Rat Genome 230 2.0 Array
GPL1355 (7,476 samples). The database thus totals
106,101 samples. Of course, this can always be extended
to include more platforms from the same species and/or
other species.
Non-redundant database
The individual GSM sample file expression values were
transformed into EF values corresponding to the expres-
sion relative to the series mean. Expression values that
have been logarithmically transformed are transformed
back to a linear scale and low expression values
dropped, that is are set to zero and don’t contribute to
the fold profile. We found that the results were rela-
tively insensitive to the cut-off value and we set this to
be 10% of the average expression value. All sample
expression profiles within a series were scaled to the
same average. The fold vales are defined as fk = 2
sk − s¯
sk + s¯







sk is the average over the series. For the
database to be searchable with cross platform response
profiles and gene lists it has to be rewritten as a data-
base of expression profiles over non-redundant gene
lists. The EF profiles across the probe sets were there-
fore mapped onto expression profiles for a non-redun-
dant gene list. In general each gene is represented by
multiple probe sets. For each platform we generated the
EF statistics for each probe set across the totality of
samples. The probe set with the most robust response
across the samples was chosen to represent the gene.
Explicitly, the probe set with the highest root mean
square deviation form zero was chosen to represent the
given gene. The number of genes defined on each plat-
form were as follows: GPL96 11,807, GPL570 15,983
genes, GPL1261 13,202 genes, GPL85 chip with 3,844
genes, GPL1355 chip with 6,341 genes. The database
totals 106,101 samples and is searchable on a reasonably
fast desktop PC in ~10 minutes per query.
Searching the database
The query profile is a statistically thresholded non-redun-
dant list of genes and associated fold values. Statistical
significance is assigned to a fold change based on a sim-
ple Student’s t-test between multiple control and treat-
ment sample expression values. This is compared to each
profile in the database by means of a simple Pearson
regression analysis, with a correlation coefficient r. The
experiments are ranked according to the significance.
The significance is measured by scaling the correlation to
the normal by a Fisher transformation and measuring the
number of standard deviations from the mean. The











N − 3, where r is the Pearson correla-
tion coefficient and N is the number of genes making up











The CMAP contains ranked lists of probes for 6,100
separate perturbagen treatments of four different human
cell lines, with the ranking based on response level rela-
tive to control. The treatments are various multiples of
1,306 different drug-like compounds. To generate
responder sets that can be used to search SPIED we
combined rankings for each separate compound treat-
ment and converted these into pseudo-fold values with
associated statistics. The pseudo-fold value is defined by
fi = 1 − 2 ri − minmax−min , where ri is the rank of the i
th
gene and min/max are the minimal/maximal ranks.
Remembering that the highest rank corresponds to the
most up-regulated gene. The SPIED was searched with
CMAP profiles corresponding to folds with a p < 0.05
threshold and with at least three replicates. This left
1,218 separate perturbagen probes. We sought to cluster
the perturbagens based on predicted target and response
profile similarity. The profiles are given in the additional
file 1 file.
Availability of SPIED
The SPIED database and associated executables are
available for download from ftp://ftp.hostedftp.com/
~GWftpFILES/SPIED/. The download consists of the
SPIED database together with executables for searching
SPIED. Source code files to generate the database and
perform query searches are provided together with the
executables. Documentation on the database, the execu-
tables and source code files is also included.
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Additional material
Additional file 1: Expression profiles derived from CMAP and
published AD studies. Expression profile signatures derived from
pooling CMAP compound treatment replicates, form corticosteroid
resistance studies and from various AD stages referenced to age
matched controls. These profiles are used to query SPIED. The data is
given as excel spreadsheets.
Additional file 2: Top scoring correlations for various expression
signature queries against SPIED. The results upon querying SPIED with
expression profiles derived from the signatures in additional file 1. The
data is given as excel spreadsheets.
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